Bavarian Nordic Transformed By GSK Vaccines Buy
Deal Valued At Up To €955m
Buying two vaccines for rabies and tick-borne encephalitis complements the recently approved smallpox and monkeypox vaccine Jynneos. Now the Danish firm needs to start selling them.
You may also be interested in...
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.